1 / 11Torrent Power | The company announced the opening of its Qualified Institutional Placement (QIP), with the floor price set at ₹1,555.75 per equity share. The floor price represents a discount of 1.60% discount to the stock’s closing price of ₹1,581.10 on Monday.
2 / 11Pricol | Automotive components maker said its board of directors has approved the acquisition of the injection-moulded plastic component division of Sundaram Auto Components Ltd, a wholly-owned subsidiary of TVS Motor Company, for ₹215.3 crore. This acquisition is expected to conclude by January 31, 2025, subject to the fulfilment of conditions in the business transfer agreement.
3 / 11Indegene | Global private equity firm Carlyle-backed CA Dawn Investments is reportedly set to sell a 2.9% stake in a healthcare tech firm through block deals, sources in the know told CNBC-TV18. The floor price for the transaction has been set at ₹615 per share, sources close to the development said. The sale could raise approximately ₹470 crore, based on the offered floor price, sources privy to the developments told CNBC-TV18.
4 / 11Hindustan Unilever | The company said it has complied with the directive of the Income Tax assessing officer to pay ₹192.55 crore, 20% of a total outstanding demand of ₹962.75 crore. This stems from a dispute over tax deduction at source (TDS) related to a ₹3,045-crore payment for acquiring India HFD intellectual property rights from GlaxoSmithKline (GSK) Group entities.
5 / 11Nazara | Gaming and sports media company announced strategic investments totalling ₹196 crore to expand its presence across the gaming, entertainment, and education sectors. This includes the acquisition of a 60% stake in Funky Monkeys Play Centers Private Ltd for ₹43.7 crore. Funky Monkeys operates 11 indoor play centres for children across India, marking Nazara’s entry into physical entertainment.
6 / 11Protean eGov Technologies | The company said it has received a work order worth approximately ₹161 crore from the Central Registry of Securitisation Asset Reconstruction and Security Interest of India (CERSAI), a Government of India undertaking. The work involves serving as the system integrator for the design, development, implementation, operations and maintenance of the Central KYC Records Registry (CKYCRR 2.0).
7 / 11Godavari Biorefineries | Ethanol player said it has signed an international licence agreement with Catalyxx Inc., granting the company exclusive rights to utilise Catalyxx’s advanced technology for converting ethanol into biobutanol and other higher alcohols. As part of this partnership, GBL will establish and operate a cutting-edge facility aimed at producing 15,000 tonnes of biobutanol and other higher alcohols annually in the first phase.
8 / 11KEC International | Infrastructure company announced that the VAT tribunal in Bangladesh has dismissed its appeal against a VAT demand order issued by the Customs, Excise & VAT Commissionerate in Dhaka. The order, dated April 29, 2024, relates to alleged discrepancies in financials and VAT returns for the period between July 2019 and June 2022. The company is actively reviewing the order and plans to challenge the decision in the High Court of Bangladesh.
9 / 11Solar Industries | Industrial explosives maker said the company, along with its subsidiary, has secured export orders worth ₹2,039 crore for the supply of defence products to international clients. The orders are for the supply of advanced defence products, to be delivered over the next four years.
10 / 11Advait Energy | The company said it has been declared a qualified bidder by Gujarat Urja Vikas Nigam Ltd (GUVNL) for the development of a portion of the western state’s 500 MW/1000 MWh standalone battery energy storage systems. The company will be responsible for setting up a 50 MW battery storage system under the contract, which has a project execution timeline of 18 months.
11 / 11Indoco Remedies | Drugmaker announced that the company has entered a strategic partnership with Clarity Pharma of the UK. This collaboration will see Indoco launch approximately 20 products in the UK over the next 18 months through Clarity Pharma, which will serve as its distributor. The company will continue to supply all the products under the existing B2B partnership to its clients.
